Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

188.28USD
20 Oct 2017
Change (% chg)

$-0.99 (-0.52%)
Prev Close
$189.27
Open
$190.59
Day's High
$192.01
Day's Low
$187.06
Volume
4,755,555
Avg. Vol
2,547,517
52-wk High
$256.80
52-wk Low
$182.80

Latest Key Developments (Source: Significant Developments)

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 07:53am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

U.S. Court issues adverse decision concerning Allergan's Restasis
Monday, 16 Oct 2017 01:45pm EDT 

Oct 16 (Reuters) - Allergan Plc :U.S. District Court for the Eastern District of Texas issues adverse trial decision concerning Restasis (cyclosporine ophthalmic emulsion) 0.05% patents.Says ‍company will appeal court's ruling regarding Restasis​.Says ‍"we are disappointed" by Federal District Court's decision on Restasis patents​.  Full Article

Allergan announces settlement on Restasis patent litigation with Innopharma
Thursday, 12 Oct 2017 04:15pm EDT 

Oct 12 (Reuters) - Allergan Plc :Allergan announces settlement on Restasis® (cyclosporine ophthalmic emulsion) 0.05% patent litigation with Innopharma, Inc..Allergan Plc - ‍additional details regarding settlement were not disclosed​.Allergan Plc - ‍as a result of settlement, all Innopharma Hatch-Waxman litigation regarding Restasis patents will be dismissed​.Allergan - will grant Innopharma licenses to market generic version of Restasis in U.S. beginning Feb 24, 2024, or earlier under certain circumstances​.Allergan - ‍under certain circumstances, co will supply, authorize Innopharma to launch an authorized generic version of Restasis on August 28, 2024​.  Full Article

Allergan says FDA accepts NDA for Ulipristal Acetate for Uterine Fibroids
Tuesday, 10 Oct 2017 08:01am EDT 

Oct 10 (Reuters) - Allergan Plc ::Announces FDA accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids.Expects Ulipristal Acetate Prescription Drug User Fee Act action date to occur in first half of 2018.  Full Article

BRIEF-Allergan says FDA accepts NDA for Ulipristal Acetate for Uterine Fibroids
Tuesday, 10 Oct 2017 08:01am EDT 

Repeats to widen distribution with no changes to text:Announces FDA accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids.Expects Ulipristal Acetate Prescription Drug User Fee Act action date to occur in first half of 2018.  Full Article

FDA approves Botox cosmetic for the temporary improvement in the appearance of forehead lines
Tuesday, 3 Oct 2017 07:31am EDT 

Oct 3 (Reuters) - Allergan Plc :FDA approves Botox cosmetic (onabotulinumtoxina) for the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults.FDA approval of Botox cosmetic for improvement in appearance of moderate to severe forehead lines realted to frontalis muscle activity in adults​.  Full Article

Allergan Plc - CFO to retire
Monday, 25 Sep 2017 07:35am EDT 

Sept 25 (Reuters) - Allergan Plc :Allergan announces Tessa Hilado, executive vice president and chief financial officer, to retire from company.Allergan Plc - Hilado will continue in her current role until a successor is named to ensure a smooth transition​.Allergan Plc - company has initiated a search to fill position.  Full Article

Allergan board authorizes new $2 billion share repurchase program
Monday, 25 Sep 2017 07:30am EDT 

Sept 25 (Reuters) - Allergan Plc :Allergan board of directors authorizes new $2 billion share repurchase program, affirms commitment to increasing cash dividend annually.Allergan Plc - ‍Reaffirms 2017 full-year guidance​.Allergan Plc - ‍Reaffirming its 2017 financial guidance issued on August 3, 2017 company also affirmed Q3 revenue projections​.Allergan Plc - ‍Company also reaffirms its commitment to pay down $3.75 billion of debt in 2018​.FY2017 earnings per share view $16.21, revenue view $15.90 billion -- Thomson Reuters I/B/E/S.Allergan Plc - ‍"Continue to believe that Allergan stock is substantially undervalued​".Q3 revenue view $4.04 billion -- Thomson Reuters I/B/E/S.  Full Article

Allergan receives refusal to file letter from FDA for Vraylar SNDA
Friday, 22 Sep 2017 04:50pm EDT 

Sept 22 (Reuters) - Allergan Plc :Allergan receives refusal to file letter from FDA for Vraylar (Cariprazine) supplemental new drug application (SNDA) for the treatment of negative symptoms in Schizophrenia.Allergan receives refusal to file letter from FDA for Vraylar (Cariprazine) supplemental new drug application (SNDA) for the treatment of negative symptoms in Schizophrenia.Allergan-‍upon its preliminary review, FDA determined SNDA for treatment of negative symptoms was not sufficiently complete to permit substantive review​.Allergan PLC - ‍Company will seek immediate guidance, and is in process of planning a meeting with FDA​.  Full Article

Photo

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.